Sep. 11 at 5:22 PM
$CELU CELU's last full books, year-end 2025, showed a
$92M loss,
$1 billion accumulated deficit, and a working-capital hole.
Since that 10K, 2026 deals such as the NexGel cash, notes, earlier IP monetization, has given them some cash but how much cash today is unknown because Q1 and Q2 10-Qs still are not filed.
In August they told the SEC the 10-Qs were late due to liquidity and no accounting staff. Nasdaq has given them notice for filings. They were supossed to give Nasdaq a plan for compliance last week. If approved they will be given til Nov 16 to file their financials.
They sold/licensed the biomaterials revenue book to stay alive, and the remaining story is unapproved cell therapy plus a non-binding MuseCell purchase forecast. Survival has been convertibles, warrants, insider loans, and liens.
You may like the potential of the company and thats fine. But it's what the company has to do to get there that matters to investors. This is not going to be good for them.
I bought Puts
